Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor ligand superfamily member 15 (TNFSF15), commonly known as tumor necrosis factor-like ligand 1A (TL1A), is a multifunctional cytokine belonging to the tumor necrosis factor (TNF) superfamily. It is primarily expressed by endothelial cells, macrophages, and dendritic cells, and acts as a potent costimulator of T cells and innate lymphoid cells by binding to its cognate receptor, death receptor 3 (DR3). This interaction activates downstream pro-inflammatory signaling pathways, such as NF-κB and MAPK, driving the secretion of inflammatory cytokines. Additionally, TL1A directly stimulates fibroblasts to promote collagen deposition and tissue remodeling, positioning it at the intersection of chronic inflammation and fibrotic pathways. Dysregulation and overexpression of TL1A are strongly implicated in the pathogenesis of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, as well as other autoimmune and fibrotic conditions like systemic sclerosis, rheumatoid arthritis, and psoriasis. Consequently, TL1A has emerged as a highly promising therapeutic target. Monoclonal antibodies targeting TL1A, such as tulisokibart, afimkibart, and duvakitug, are designed to neutralize both soluble and membrane-bound forms of the cytokine, thereby blocking the TL1A-DR3 signaling axis to alleviate tissue inflammation and reverse fibrotic changes.
Monoclonal antibody that binds to and neutralizes soluble and membrane-bound TL1A, preventing its interaction with death receptor 3 (DR3) and decoy receptor 3 (DcR3), thereby inhibiting downstream inflammatory and fibrotic signaling pathways.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor necrosis factor ligand superfamily member 15 (TL1A) (TL1A).